ConductScience.org, home

Paper42446728

Protein kinases as therapeutic targets in Alzheimer's disease: challenges, insights, and new frontiers.

Tak C and 2 others. Med Chem Res, 2026. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Protein kinases as therapeutic targets in Alzheimer's disease: challenges, insights, and new frontiers. Papers, record 42446728. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42446728

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Protein kinases as therapeutic targets in Alzheimer's disease: challenges, insights, and new frontiers.
PubMed
Journal
Med Chem Res
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-11-03
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Tak CChanwool
2Bhujbal SPSwapnil P
3Hah JMJung-Mihttps://orcid.org/0000-0001-6439-0405

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Alzheimer DiseaseMajor topic
Protein KinasesMajor topic
Protein Kinase InhibitorsMajor topic
Humans
Animals
tau Proteins
Molecular Targeted Therapy

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
NRF-RS-2020-NR049583 (Center for Proteinopathy)National Research Foundation of Korea grantPubMedPubMed
NRF-RS-2024-00333784 (J.-M.H.)National Research Foundation of KoreaNRFRS202400PubMedNIH RePORTER

Download CSV of grants

References127

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
112615961GSK-3: tricks of the trade for a multi-tasking kinase.J Cell Sci2003https://conductscience.org/library/papers/12615961PubMed
215717052The blood-brain barrier and neurotherapeutics.NeuroRx2005https://conductscience.org/library/papers/15717052PubMed
322102280Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib.J Biol Chem2012https://conductscience.org/library/papers/22102280PubMed
423431164DLK initiates a transcriptional program that couples apoptotic and regenerative responses to axonal injury.Proc Natl Acad Sci U S A2013https://conductscience.org/library/papers/23431164PubMed
524904272GSK-3β, a pivotal kinase in Alzheimer disease.Front Mol Neurosci2014https://conductscience.org/library/papers/24904272PubMed
61789684Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment.Ann Neurol1991https://conductscience.org/library/papers/1789684PubMed
712471243The protein kinase complement of the human genome.Science2002https://conductscience.org/library/papers/12471243PubMed
818798283The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity.J Neurosci Res2009https://conductscience.org/library/papers/18798283PubMed
927354962Linking multiple pathogenic pathways in Alzheimer's disease.World J Psychiatry2016https://conductscience.org/library/papers/27354962PubMed
1010696521Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms.Clin Exp Pharmacol Physiol2000https://conductscience.org/library/papers/10696521PubMed
1111724784Jun NH2-terminal kinase (JNK) interacting protein 1 (JIP1) binds the cytoplasmic domain of the Alzheimer's beta-amyloid precursor protein (APP).J Biol Chem2002https://conductscience.org/library/papers/11724784PubMed
1228257805
JNK1 and JNK3 play a significant role in both neuronal apoptosis and necrosis. Evaluation based on in vitro approach using tert-butylhydroperoxide induced oxidative stress in neuro-2A cells and perturbation through 3-aminobenzamide.
Toxicol In Vitro2017https://conductscience.org/library/papers/28257805PubMed
1312606497Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo.Diabetes2003https://conductscience.org/library/papers/12606497PubMed
141759558Neuropathological stageing of Alzheimer-related changes.Acta Neuropathol1991https://conductscience.org/library/papers/1759558PubMed
1539065802Computational Design of Novel Tau-Tubulin Kinase 1 Inhibitors for Neurodegenerative Diseases.Pharmaceuticals (Basel)2024https://conductscience.org/library/papers/39065802PubMed
1638401188Discovery of N-(5-amido-2-methylphenyl)-5-methylisoxazole-3-carboxamide as dual CSF-1R/c-Kit Inhibitors with improved stability and BBB permeability.Eur J Med Chem2024https://conductscience.org/library/papers/38401188PubMed
1729863360Dual Leucine Zipper Kinase Inhibitors for the Treatment of Neurodegeneration.J Med Chem2018https://conductscience.org/library/papers/29863360PubMed
1828440222Dual leucine zipper kinase-dependent PERK activation contributes to neuronal degeneration following insult.Elife2017https://conductscience.org/library/papers/28440222PubMed
1933944571Discovery of Potent and Brain-Penetrant Tau Tubulin Kinase 1 (TTBK1) Inhibitors that Lower Tau Phosphorylation In Vivo.J Med Chem2021https://conductscience.org/library/papers/33944571PubMed
2028099414Neurotoxic reactive astrocytes are induced by activated microglia.Nature2017https://conductscience.org/library/papers/28099414PubMed

See all 127 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42773735Phytochemical Analysis Using LC-MS/MS and Anticancer Activity of Asphodelus tenuifolius Roots: Cell Cycle Arrest, Apoptosis, and In Silico Insights.Chem Biodivers2026https://conductscience.org/library/papers/42773735PubMed
42749965Quercetin-Based Nanotherapeutics for Targeted Drug Delivery in Alzheimer's Disease: Comparative Insights into Molecular Mechanisms, Blood-Brain Barrier Targeting and Therapeutic Perspectives.Mol Neurobiol2026https://conductscience.org/library/papers/42749965PubMed

Download CSV of cited by

Genes8

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42446728

GET https://conductscience.org/api/papers/v1/42446728/references?page=2